Development of Nephrotic Syndrome in a Patient with Rheumatoid Arthritis Treated with Certolizumab

Butendieck, Ronald R.; Bhattacharya, Tanya; Geiger, Xochiquetzal J.

doi:10.3899/jrheum.160147

Cited by 3 publications

(2 citation statements)

References 7 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is biological plausibility for the relationship between certolizumab and MCD. First, prior reports demonstrated similar timing of TNF-α inhibitor initiation and the development of nephrotic syndrome 3-12 months after initiation 3,4,5,6 . Second, TNF-α blockade has been shown to shift the Th cell response toward Th2 and the promotion of humoral immunity 7,8 and MCD has been associated with elevated levels of various Th2 cytokines 9,10 .…”

Section: To the Editormentioning

confidence: 88%

“…Leong and Fung-liu reported the case of a patient treated with certolizumab for Crohn disease who subsequently developed focal segmental glomerulosclerosis 5 . Most recently, Butendieck, et al published a case of a patient treated with certolizumab for RA who subsequently developed membranous glomerulonephropathy 6 . Both these patients demonstrated gradual resolution of their renal disease after discontinuation of certolizumab.…”

Section: To the Editormentioning

confidence: 99%

See 1 more Smart Citation

A Case of Minimal Change Disease in a Patient with Rheumatoid Arthritis Treated with Certolizumab

Hwang

Sawatsky

2019

J Rheumatol

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 88%

Section: To the Editormentioning

confidence: 99%

A Case of Minimal Change Disease in a Patient with Rheumatoid Arthritis Treated with Certolizumab

Hwang

Sawatsky

2019

J Rheumatol

View full text Add to dashboard Cite

Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review

et al. 2021

View full text Add to dashboard Cite

Objective Our objective was to update the understanding of the development of paradoxical immune-mediated glomerular disorders (IGDs) in patients with rheumatic diseases treated with biologics and targeted synthetic drugs (ts-drugs). Methods A systematic literature review was performed by searching PubMed for articles published between 1 January 2014 and 1 January 2020 reporting on the development of IGD in adult patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or systemic lupus erythematosus (SLE) who were receiving biologics or ts-drugs. IGDs were classified on the basis of clinical, laboratory and histopathological data as (1) glomerulonephritis associated with systemic vasculitis (GNSV), (2) isolated autoimmune renal disorder (IARD) or (3) glomerulonephritis in SLE and in lupus-like syndrome (GNLS). The World Health Organization-Uppsala Monitoring Centre (WHO-UMC) system for standardized case causality assessment was applied to evaluate the causal relationship between IGD and specific drugs. The classification was based on a six-category scale, where the “certain” and “probable” categories were deemed clinically relevant relationships. Results The literature search retrieved 875 articles. Of these, 16 articles reported IGD data, for a total of 25 cases. According to the WHO-UMC assessment, the strength of the causal relationship between IGDs and investigated drugs was higher for anti-tumor necrosis factor-α agents (a clinically relevant relationship was found in four of six cases), abatacept (one of two cases), tocilizumab (two cases), ustekinumab (one case) and tofacitinib (one case) than for rituximab (nine cases), belimumab (three cases) or secukinumab (one case), which showed a weak causal relationship with these paradoxical events. No cases associated with apremilast or baricitinib were found. The retrieved cases were classified as 11 GNLS, seven IARD and seven GNSV. Conclusions Biologics and ts-drugs can cause IGDs. These events are rare, and the causative effect of a specific drug is hard to establish. When a patient is suspected of having an IGD, the drug should be discontinued, and treatment for the new-onset renal disorder should be promptly started.

show abstract

Certolizumab pegol

2016

Reactions Weekly

View full text Add to dashboard Cite

Development of Nephrotic Syndrome in a Patient with Rheumatoid Arthritis Treated with Certolizumab

Cited by 3 publications

References 7 publications

A Case of Minimal Change Disease in a Patient with Rheumatoid Arthritis Treated with Certolizumab

A Case of Minimal Change Disease in a Patient with Rheumatoid Arthritis Treated with Certolizumab

Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review

Certolizumab pegol

Contact Info

Product

Resources

About